美股A股
StockGist
Back
8-K2026-02-17· grok-4-1-fast-non-reasoning

QUCY · Mainz Biomed N.V.

0001213900-26-016890

SEC filing

Summary

Mainz Biomed N.V. entered a Securities Purchase Agreement with David E. Lazar for a $6 million private placement of convertible preferred shares in two closings, with the first $3 million closing completed on February 13, 2026. Lazar was appointed as temporary non-executive director and Chair of the Board, with rights to nominate additional directors post-shareholder approval.

Key takeaways